Skip to main content

Table 3 Regression analysis of weight loss in the study population

From: Serum TSH, 25(OH) D and phosphorus levels predict weight loss in individuals with diabetes/prediabetes and morbid obesity: a single-center retrospective cohort analysis

 

Model 1, no LT4 replacement group (n = 176)

Model 2, no LT4 replacement group (n = 176)

Model 3, anti-thyroid antibody negative and no LT4 replacement group (n = 155)

Model 4, The entire group (n = 285)

R2 = 0.52, F = 10.1, p < .001

R2 = 0.54, F = 11.5, p < .001

R2 = 0.51, F = 9.1, p < .001

R2 = 0.43, F = 13.4, p < .001

Beta

p-value

VIF

Beta

p-value

VIF

Beta

p-value

VIF

Beta

p-value

VIF

TSH, last visit

−0.14

.046

1.20

− 0.13

.081

1.18

− 0.15

.006

1.11

fT4, last visit

− 0.01

.926

1.13

− 0.01

.170

1.11

0.03

.532

1.12

fT3, last visit

−0.04

.541

1.08

− 0.00

.986

1.06

−0.06

.271

1.10

SPINA-GD, last visit

0.01

.870

1.23

SPINA-GT, last visit

0.09

.167

1.16

Calcium, last visit

0.08

.203

1.18

0.08

.257

1.20

Phosphorus, last visit

0.18

.008

1.27

0.16

.021

1.30

0.20

.006

1.21

0.13

.019

1.21

25(OH)vit D, last visit

0.14

.032

1.11

0.13

.050

1.12

0.16

.022

1.11

0.16

.002

1.09

Parathormone, last visit

0.00

.998

1.18

0.02

.973

1.20

0.02

.825

1.24

−0.09

.095

1.18

BMI, at baseline

0.36

<.001

1.77

0.39

<.001

1.67

0.39

<.001

1.85

0.34

<.001

1.52

Orlistat,a

0.21

.016

1.94

0.21

.011

1.84

0.19

.050

2.01

0.19

.003

1.56

Metformina,

0.20

.011

1.58

0.21

.004

1.49

0.20

.017

1.61

0.15

.015

1.45

Acarbosea

0.04

.559

1.49

0.07

.356

1.44

0.08

.308

1.8

0.10

.089

1.32

Exenatide, a

0.04

.587

1.56

0.02

.821

1.59

0.02

.772

1.63

0.08

.232

1.58

SGLT-2 inh. a

−0.03

.693

1.55

0.00

.996

1.55

−0.05

.511

1.55

−0.02

.710

1.58

Fluoxetinea

0.04

.618

1.47

0.03

.725

1.50

0.00

.959

1.58

0.02

.768

1.37

  1. aCumulative doses